Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling

Current Neurovascular Research

Volumn 4, Issue 3, 2007, Pages 194-204

  Zhao, Zhong Chong ^a   Yan, Chen Shang ^a   Maiese, Kenneth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Diabetes; Endothelial cells; Erythropoietin; Glucose; Growth factors; GSK 3 ; Oxidative stress; SB21; Vascular disease; Wingless; Wnt; Wnt1 antibody

Indexed keywords

ERYTHROPOIETIN; GLUCOSE; GLYCOGEN SYNTHASE KINASE; GLYCOSYLATED PROTEIN; NEUTRALIZING ANTIBODY; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DNA DEGRADATION; GENE EXPRESSION; HEMATOPOIETIC CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; BRAIN; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIAL CELLS; ENZYME INHIBITORS; ERYTHROPOIETIN; GLUCOSE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; WNT1 PROTEIN;

EID: 34547797469     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720207781387150     Document Type: Article

References (77)

1. Abbott, NJ, Hughes, CC, Revest, PA, Greenwood, J. (1992) Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 103(Pt 1): 23-37.
2. Abe, K, Takeichi, M. (2007) NMDA-receptor activation induces calpain-mediated beta-catenin cleavages for triggering gene expression. Neuron 53: 387-97.
3. Avasarala, JR, Konduru, SS. (2005) Recombinant erythropoietin downregulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis. J Mol Neurosci 25: 183-9.
4. Bahlmann, FH, Song, R, Boehm, SM, Mengel, M, von Wasielewski, R, Lindschau, C, Kirsch, T, de Groot, K, Laudeley, R, Niemczyk, E, Guler, F, Menne, J, Haller, H, Fliser, D. (2004) Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110: 1006-12.
5. Balaraman, Y, Limaye, AR, Levey, AI, Srinivasan, S. (2006) Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63: 1226-35.
6. Berent-Spillson, A, Russell, JW. (2007) Metabotropic glutamate receptor 3 protects neurons from glucose-induced oxidative injury by increasing intracellular glutathione concentration. J Neurochem 101: 342-54.
7. Bierer, R, Peceny, MC, Hartenberger, CH, Ohls, RK. (2006) Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 118: e635-40.
8. Bournat, JC, Brown, AM, Soler, AP. (2000) Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. J Neurosci Res 61: 21-32.
9. Chong, ZZ, Kang, JQ, Maiese, K. (2003a) Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 23: 320-30.
10. Chong, ZZ, Kang, JQ, Maiese, K. (2003b) Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 138: 1107-1118.
11. Chong, ZZ, Kang, JQ, Maiese, K. (2002) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106: 2973-9.
12. Chong, ZZ, Li, F, Maiese, K. (2007a) Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal 19: 1150-62.
13. Chong, ZZ, Li, F, Maiese, K. (2005a) Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2: 387-99.
14. Chong, ZZ, Li, F, Maiese, K. (2005b) Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 75: 207-46.
15. Chong, ZZ, Li, F, Maiese, K. (2005c) Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 49: 1-21.
16. Chong, ZZ, Li, F, Maiese, K. (2007b) The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 19: 263-72.
17. Chong, ZZ, Li, FQ, Maiese, K. (2005d) Employing new cellular therapeutic targets for Alzheimer's disease: A change for the better? Curr Neurovasc Res 2: 55-72.
18. Chong, ZZ, Maiese, K. (2007) Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 150: 839-50.
19. Chong, ZZ, Maiese, K. (2004) Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 19: 495-504.
20. Cohen, SM, Furey, TS, Doggett, NA, Kaufman, DG. (2006) Genome-wide sequence and functional analysis of early replicating DNA in normal human fibroblasts. BMC Genomics 7: 301.
21. Daneman, D. (2006) Type 1 diabetes. Lancet 367: 847-58.
22. Duarte, AI, Proenca, T, Oliveira, CR, Santos, MS, Rego, AC. (2006) Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 55: 2863-70.
23. Eldar-Finkelman, H, Argast, GM, Foord, O, Fischer, EH, Krebs, EG. (1996) Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proc Natl Acad Sci USA 93: 10228-33.
24. Grant, SF, Thorleifsson, G, Reynisdottir, I, Benediktsson, R, Manolescu, A, Sainz, J, Helgason, A, Stefansson, H, Emilsson, V, Helgadottir, A, Styrkarsdottir, U, Magnusson, KP, Walters, GB, Palsdottir, E, Jonsdottir, T, Gudmundsdottir, T, Gylfason, A, Saemundsdottir, J, Wilensky, RL, Reilly, MP, Rader, DJ, Bagger, Y, Christiansen, C, Gudnason, V, Sigurdsson, G, Thorsteinsdottir, U, Gulcher, JR, Kong, A, Stefansson, K. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38: 320-3.
25. Guo, YF, Xiong, DH, Shen, H, Zhao, LJ, Xiao, P, Guo, Y, Wang, W, Yang, TL, Recker, RR, Deng, HW. (2006) Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 43: 798-803.
26. He, B, Reguart, N, You, L, Mazieres, J, Xu, Z, Lee, AY, Mikami, I, McCormick, F, Jablons, DM. (2005) Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24: 3054-8.
27. Henry, DH, Bowers, P, Romano, MT, Provenzano, R. (2004) Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164: 262-76.
28. Howlett, KF, Sakamoto, K, Yu, H, Goodyear, LJ, Hargreaves, M. (2006) Insulin-stimulated insulin receptor substrate-2-associated phosphatidy linositol 3-kinase activity is enhanced in human skeletal muscle after exercise. Metabolism 55: 1046-52.
29. Huber, JD, VanGilder, RL, Houser, KA. (2006) Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 291: H2660-8.
30. Jozwiak, J, Kotulska, K, Grajkowska, W, Jozwiak, S, Zalewski, W, Oldak, M, Lojek, M, Rainko, K, Maksym, R, Lazarczyk, M, Skopinski, P, Wlodarski, P. (2007) Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev 29: 273-80.
31. Kanazawa, A, Tsukada, S, Sekine, A, Tsunoda, T, Takahashi, A, Kashiwagi, A, Tanaka, Y, Babazono, T, Matsuda, M, Kaku, K, Iwamoto, Y, Kawamori, R, Kikkawa, R, Nakamura, Y, Maeda, S. (2004) Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 75: 832-43.
32. Laakso, M. (2001) Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 249: 225-35.
33. Li, F, Chong, ZZ, Maiese, K. (2006a) Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD(+) Precursor Nicotinamide. Curr Med Chem 13: 883-95.
34. Li, F, Chong, ZZ, Maiese, K. (2004) Erythropoietin on a Tightrope: Balancing Neuronal and Vascular Protection between Intrinsic and Extrinsic Pathways. Neurosignals 13: 265-89.
35. Li, F, Chong, ZZ, Maiese, K. (2006b) Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res 3: 187-201.
36. Li, F, Chong, ZZ, Maiese, K. (2005) Vital elements of the wnt-frizzled signaling pathway in the nervous system. Curr Neurovasc Res 2: 331-40.
37. Li, F, Chong, ZZ, Maiese, K. (2006c) Winding through the WNT pathway during cellular development and demise. Histol Histopathol 21: 103-24.
38. Lin, CL, Wang, JY, Huang, YT, Kuo, YH, Surendran, K, Wang, FS. (2006) Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 17: 2812-20.
39. Maiese, K, Chong, ZZ, Li, F. (2005a) Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res 2: 425-46.
40. Maiese, K, Chong, ZZ, Shang, YC. (2007a) Mechanisitic insights into diabetes mellitus and oxidative stress. Curr Med Chem 14: 1689-1699.
41. Maiese, K, Li, F, Chong, ZZ. (2005b) Erythropoietin and cancer. JAMA 293: 1858-1859.
42. Maiese, K, Li, F, Chong, ZZ. (2004) Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 25: 577-583.
43. Maiese, K, Li, F, Chong, ZZ. (2005c) New avenues of exploration for erythropoietin. JAMA 293: 90-5.
44. Maiese, K, Morhan, SD, Chong, ZZ. (2007b) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 4: 63-71.
45. Maiorana, A, O'Driscoll, G, Goodman, C, Taylor, R, Green, D. (2002) Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes. Diabetes Res Clin Pract 56: 115-23.
46. Mason-Garcia, M, Beckman, BS, Brookins, JW, Powell, JS, Lanham, W, Blaisdell, S, Keay, L, Li, SC, Fisher, JW. (1990) Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 38: 969-75.
47. Menon, MP, Karur, V, Bogacheva, O, Bogachev, O, Cuetara, B, Wojchowski, DM. (2006) Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 116: 683-94.
48. Mikati, MA, Hokayem, JA, Sabban, ME. (2007) Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at p10. Epilepsia 48: 175-81.
49. Mojiminiyi, OA, Abdella, NA, Zaki, MY, El Gebely, SA, Mohamedi, HM, Aldhahi, WA. (2006) Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. Diabet Med 23: 839-44.
50. Moon, C, Krawczyk, M, Paik, D, Coleman, T, Brines, M, Juhaszova, M, Sollott, SJ, Lakatta, EG, Talan, MI. (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316: 999-1005.
51. Mussmann, R, Geese, M, Harder, F, Kegel, S, Andag, U, Lomow, A, Burk, U, Onichtchouk, D, Dohrmann, C, Austen, M. (2007) Inhibition of glycogen synthase kinase (GSK) 3 promotes replication and survival of pancreatic beta cells. J Biol Chem 282: 12030-7.
52. Namiuchi, S, Kagaya, Y, Ohta, J, Shiba, N, Sugi, M, Oikawa, M, Kunii, H, Yamao, H, Komatsu, N, Yui, M, Tada, H, Sakuma, M, Watanabe, J, Ichihara, T, Shirato, K. (2005) High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45: 1406-12.
53. Niiya, Y, Abumiya, T, Shichinohe, H, Kuroda, S, Kikuchi, S, Ieko, M, Yamagishi, S, Takeuchi, M, Sato, T, Iwasaki, Y. (2006) Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species. Brain Res 1108: 179-87.
54. Nurmi, A, Goldsteins, G, Narvainen, J, Pihlaja, R, Ahtoniemi, T, Grohn, O, Koistinaho, J. (2006) Antioxidant pyrrolidine dithiocarbamate activates Akt-GSK signaling and is neuroprotective in neonatal hypoxiaischemia. Free Radic Biol Med 40: 1776-84.
55. Pagano, G, Bargero, G, Vuolo, A, Bruno, G. (1994) Prevalence and clinical features of known type 2 diabetes in the elderly: a population-based study. Diabet Med 11: 475-9.
56. Quinn, L. (2001) Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. Nurs Clin North Am 36: 175-92, v.
57. Rhee, CS, Sen, M, Lu, D, Wu, C, Leoni, L, Rubin, J, Corr, M, Carson, DA. (2002) Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21: 6598-605.
58. Ryan, EA, Imes, S, Wallace, C. (2004) Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27: 1028-32.
59. Santhanam, AV, Katusic, ZS. (2006) Erythropoietin and cerebral vascular protection: role of nitric oxide. Acta Pharmacol Sin 27: 1389-94.
60. Saydah, SH, Fradkin, J, Cowie, CC. (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291: 335-42.
61. Schnaider Beeri, M, Goldbourt, U, Silverman, JM, Noy, S, Schmeidler, J, Ravona-Springer, R, Sverdlick, A, Davidson, M. (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63: 1902-7.
62. Schumann, C, Triantafilou, K, Krueger, S, Hombach, V, Triantafilou, M, Becher, G, Lepper, PM. (2006) Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm 2006: 18061.
63. Silverberg, DS, Wexler, D, Blum, M, Tchebiner, JZ, Sheps, D, Keren, G, Schwartz, D, Baruch, R, Yachnin, T, Shaked, M, Schwartz, I, Steinbruch, S, Iaina, A. (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141-6.
64. Silverberg, DS, Wexler, D, Iaina, A, Steinbruch, S, Wollman, Y, Schwartz, D. (2006) Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 38: 295-310.
65. Sohmiya, M, Kakiba, T, Kato, Y. (1998) Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur J Endocrinol 139: 367-70.
66. Symeonidis, A, Kouraklis-Symeonidis, A, Psiroyiannis, A, Leotsinidis, M, Kyriazopoulou, V, Vassilakos, P, Vagenakis, A, Zoumbos, N. (2006) Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 85: 79-85.
67. Teramo, K, Kari, MA, Eronen, M, Markkanen, H, Hiilesmaa, V. (2004) High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia 47: 1695-703.
68. Thomas, MC, Cooper, ME, Tsalamandris, C, MacIsaac, R, Jerums, G. (2005) Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 165: 466-9.
69. Troisi, RJ, Cowie, CC, Harris, MI. (2000) Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 284: 3157-9.
70. Um, M, Gross, AW, Lodish, HF. (2007) A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19: 634-45.
71. Urao, N, Okigaki, M, Yamada, H, Aadachi, Y, Matsuno, K, Matsui, A, Matsunaga, S, Tateishi, K, Nomura, T, Takahashi, T, Tatsumi, T, Matsubara, H. (2006) Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98: 1405-13.
72. van der Meer, P, Voors, AA, Lipsic, E, Smilde, TD, van Gilst, WH, van Veldhuisen, DJ. (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44: 63-7.
73. Wang, H, MacNaughton, WK. (2005) Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res 65: 8604-7.
74. Wright, WS, Longo, KA, Dolinsky, VW, Gerin, I, Kang, S, Bennett, CN, Chiang, SH, Prestwich, TC, Gress, C, Burant, CF, Susulic, VS, Macdougald, OA. (2007) Wnt10b Inhibits Obesity in ob/ob and Agouti Mice. Diabetes 56: 295-303.
75. Yoshimura, T, Kawano, Y, Arimura, N, Kawabata, S, Kikuchi, A, Kaibuchi, K. (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120: 137-49.
76. You, L, He, B, Uematsu, K, Xu, Z, Mazieres, J, Lee, A, McCormick, F, Jablons, DM. (2004) Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res 64: 3474-8.
77. Yue, TL, Bao, W, Gu, JL, Cui, J, Tao, L, Ma, XL, Ohlstein, EH, Jucker, BM. (2005) Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54: 554-62.